Stockreport

Innate Pharma third quarter 2019 report

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni $79.1 million (€71.4 millionii) in gross proceeds from our IPO on the Nasdaq [Read more]